Nexus Infrastructure – ‘profits in line’ (are they?), ‘order book provides good visibility of earnings’ (does it?)…
Tom Winnifrith described the deal under which AIM-listed E-Therapeutics (ETX) repurchased a company called Searchbolt (having spun it off some while back) as stinking like a pile of rotting kippers at the height of summer. In the event, two directors of E-Therapeutics ended up with (between them) almost 3.4 million shares in the company from the transaction. Now the CEO (who accounted for 3,350,228 of those shares – plus a cash sum to cover capital gains tax) has quit with immediate effect.
Tom Winnifrith has already stuck the knife into e-Therapeutics (ETX) over its related party deal to re-buy Searchbolt – a company it had previously spun off as non-core (see HERE). Noting the lack of recent accounts, following an extension of its accounting period, there have been no numbers since the period ending July 2014 – figures which were filed very late (14 months post period), and which showed net current assets of MINUS £12,615 and net assets of MINUS £166,078 and £831,528 of losses had been racked up over about seven years (with about £45,000 during the year to July 2014).
e-Therapeutics (ETX) has just issued this statement about the >35% jump in its share price in the last few days. In short, its board has admitted that it thinks price sensitive information has leaked from the company. “Big deal”, I hear our regular readers cry, “this is what we expect on AIM”. Sadly I have to agree with this sentiment, but this instance of seemingly clear-cut insider dealing has caught my eye. This is because, on this occasion, the London Stock Exchange’s AIM Regulation team and Financial Conduct Authority should have an easy time of catching the culprit or culprits. That is, if they are awake. It is, after all, Thursday afternoon.
Search ShareProphets |
Recent Comments |